__NUXT_JSONP__("/drugs/Vulinacimab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"2250342-36-8",chebiId:b,chemicalFormula:b,definition:"A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.",fdaUniiCode:"SA09JNQ24D",identifier:"C156172",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C93170"],synonyms:["Anti-VEGFR2 Monoclonal Antibody HLX06","HLX 06","HLX-06","HLX06","VULINACIMAB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FVulinacimab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Vulinacimab","","2021-10-30T13:34:18.943Z")));